REFERENCES
- Mizutani K, Terasaki PI, Bignon JD, et al. Association of kidney transplant failure and antibodies against MICA. Hum Immunol. 2006; 67: 683–691
- Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007; 7: 408–415
- Barama A, Oza U, Panek R, et al. Effect of recipient sensitization (peak PRA) on graft outcome in haplomatched living related kidney transplant. Clin Transplant. 2000; 14: 212–217
- Zhou YC, Cecka JM. Sensitisation in renal transplantation. Clin Transplant. 1991; 313–323
- Montgomery RA, Zachary AA, Racusenen LC, et al. Plasmapheresis and intravenous immunoglobulin provide effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation. 2000; 70: 887–895
- Thielke J, DeChristopher PJ, Sankaty H, et al. Highly successful living donor kidney transplantation after conversion negative of a previously positive flow cytometery cross-match by pretransplant plasmapheresis. Transplant Proc. 2005; 37: 643–644
- Jordon SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits cross-match positivity and allows for successful transplantation on incompatible organs in living donor and cadaver recipients. Transplantation. 2003; 76: 631–636
- Magee CC. Transplantation across positively incompatible immunological barriers. Transplant Int. 2006; 19: 87–97
- Allison AC, Eugui EM. Mechanism of action of mycophenolate mofetil in preventing acute and chronic rejection. Transplantation. 2005; 80S: 181–190
- Worthington JE, Robson AJ, Sheldon S, Langton A, Martin S. Comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for detection of HLA specific antibodies. Hum Immunol. 2001; 62: 1178–1184
- Karpinski M, Rush D, Jeffery J, et al. Flow cytometric cross matching in primary renal transplant recipients with negative anti-human globulin enhanced cytotoxicity cross-match. JASN. 2001; 2: 2807–2814
- Susal C, Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA cl II but not against HLA cl I. Hum Immunol. 2004; 65: 810–816
- Pollinger HS, Stegall MD, Moore SB, et al. Kidney transplant in patients with antibodies against donor HLA cl II. Am J Transplant. 2007; 7: 857–863
- Jordon SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease. Report of the NIH IG02 Trial. JASN. 2004; 15: 3256–3262
- Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transplant International. 2004; 17: 1–8
- Tahir MT, Mehra NK, Singal DP, Dash SC, Singh R, Mehta SN. Effect of PRA on living related donor kidney transplant—Indian experience. Transplant Immunology. 1994; 2: 238–242